Globus Medical (NYSE:GMED) Stock Rating Lowered by BMO Capital Markets

Globus Medical (NYSE:GMED) was downgraded by equities researchers at BMO Capital Markets from an “outperform” rating to a “market perform” rating in a research note issued on Friday, Marketbeat reports. They presently have a $78.00 target price on the medical device company’s stock, down from their prior target price of $94.00. BMO Capital Markets‘s price objective would suggest a potential downside of 3.85% from the company’s previous close.

A number of other analysts have also issued reports on the company. Royal Bank Of Canada lowered their target price on Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, October 1st. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. Truist Financial cut their price target on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. UBS Group began coverage on Globus Medical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price objective for the company. Finally, Wells Fargo & Company lowered their price objective on shares of Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and an average target price of $98.23.

Globus Medical Price Performance

GMED stock opened at $81.13 on Friday. Globus Medical has a 52-week low of $60.36 and a 52-week high of $101.40. The company has a 50-day moving average of $77.44 and a two-hundred day moving average of $83.29. The stock has a market capitalization of $10.89 billion, a price-to-earnings ratio of 20.75, a price-to-earnings-growth ratio of 1.40 and a beta of 0.98.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The business had revenue of $763.72 million for the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The firm’s revenue for the quarter was down .7% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts expect that Globus Medical will post 4.99 EPS for the current fiscal year.

Insider Activity

In related news, Director Ann Rhoads sold 5,000 shares of the stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the sale, the director owned 35,384 shares in the company, valued at approximately $3,007,640. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 60,000 shares of company stock valued at $4,838,400. Insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

A number of hedge funds have recently modified their holdings of GMED. Paradigm Capital Management Inc. NY bought a new stake in shares of Globus Medical during the second quarter valued at approximately $70,042,000. American Capital Management Inc. acquired a new position in shares of Globus Medical in the second quarter valued at $51,599,000. Hawk Ridge Capital Management LP bought a new position in Globus Medical in the first quarter worth $43,078,000. Arrowstreet Capital Limited Partnership lifted its position in Globus Medical by 107.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock worth $78,656,000 after purchasing an additional 471,875 shares during the period. Finally, Janus Henderson Group PLC lifted its position in Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after purchasing an additional 328,217 shares during the period. Institutional investors own 95.16% of the company’s stock.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter EPS was $1.23, above the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, potentially supporting shareholder returns. Third-quarter results and repurchase announcement
• Positive Sentiment: The recently announced acquisition of Synaptive Medical adds cranial-neurosurgery technology and could broaden Globus Medical’s position in that market. Synaptive Medical acquisition
• Neutral Sentiment: Director Ann Rhoads sold 5,000 shares for $425,000, reducing her holdings by 12.38%. One director’s sale is not necessarily a signal about the company’s outlook. SEC ownership filing
• Negative Sentiment: Third-quarter revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year revenue guidance of $3.1 billion is also below the $3.2 billion consensus. EPS guidance of $4.95–$5.05 is broadly in line with expectations, but the sales miss and softer revenue outlook may outweigh the earnings beat. Q3 sales and earnings report

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.